HSPB8 (heat shock 22kDa protein 8) by Bollino, D & Aurelian, L
  
 
 
   
Gene Section 
Review 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12) 907 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
HSPB8 (heat shock 22kDa protein 8) 
Dominique Bollino, Laure Aurelian 
University of Maryland, Baltimore, USA (DB, LA) 
 
Published in Atlas Database: March 2014 
Online updated version : http://AtlasGeneticsOncology.org/Genes/HSPB8ID43743ch12q24.html 
DOI: 10.4267/2042/54369 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Abstract 
Review on HSPB8, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: CMT2L, DHMN2, E2IG1, H11, 
HMN2, HMN2A, HSP22 
HGNC (Hugo): HSPB8 
Location: 12q24.23 
DNA/RNA 
Description 
HspB8 maps on chromosome 12, at 12q24.23, 
spanning 40.2 kb from 119611731 to 119658934. 
Transcription produces 5 alternatively spliced 
mRNAs ranging from 244 aa to 27 aa in length, 
only 3 of which contain an α-crystallin domain and 
are coding. There are 3 probable alternative 
promoters and 2 non-overlapping alternative last 
exons. 
Transcription 
Transcription produces 5 alternatively spliced 
mRNAs, which differ by truncation of the 3' end 
and the presence or absence of a cassette exon. See 
below the features of the splice variants. 
A: Accessions from pericardium, thalamus, caudate 
nucleus, placenta, and subthalamic nucleus. 
Complete mRNA, 1526 bp long, predicted protein 
is 244 aa, contains one α-crystallin domain. 
B: Accessions from placenta cot, placenta, brain 
and eye. Complete mRNA, 2154 bp long, predicted 
protein 196 aa, contains one α-crystallin domain. 
C: Accessions from placenta and placenta cot. 
Complete mRNA, 1795 bp long, predicted protein 
130 aa, contains one α-crystallin domain. 
D: Accessions from liver, spleen, head, and lung. 
Partial mRNA, 1337 bp, best predicted protein 
would have 60 aa, appears to be non-coding. 
 
 
The 5 mRNA splice variants of HspB8. The empty light blue boxes represent the untranslated regions, the red boxes are exons, 
and the wide colored boxes are introns. Exon size is proportional to length. Introns of the same color are identical. The purple 
introns are upstream open reading frames. The solid black vertical lines indicate validated cap sites at the 5' end and the dotted 
black lines indicate validated polyadenylation sites at the 3' end. 
HSPB8 (heat shock 22kDa protein 8) Bollino D, Aurelian L 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12) 908 
 
Schematic representation of the HspB8 protein, highlighting its phosphorylation sites (red arrows), naturally occurring mutations 
(orange type) and mutations that do not occur in nature (green). See the Mutation section below for more information on 
mutations. 
 
E: Partial mRNA, 382 bp, best predicted protein 
would have 27 aa, appears to be non-coding. 
Pseudogene 
Unknown. 
Protein 
Description 
HspB8 is a relatively new member of the family of 
mammalian small heat shock proteins (sHsps), a 
distinct family subset with monomer molecular 
masses generally in the 12-43 kDa range. HspB8 is 
one of 10 sHsps identified so far in the human 
genome (Kappé et al., 2003). It was cloned in 2000 
from human melanoma and cervical cancer cells 
based on its homology to the protein kinase (PK) 
domain of the large subunit of herpes simplex virus 
type 2 (HSV-2) ribunucleotide reductase (R1), 
known as ICP10PK, and was named H11. The 
molecular mass of HspB8 is 22 kDa. It shares with 
the other sHsps, a conserved amino acid sequence, 
called the 'α-crystallin domain' that is located in the 
C-terminal part of the molecule. However, HspB8 
also classifies as an atypical serine/threonine 
protein kinase (PK). Its catalytic core retains motifs 
I-III that are required for kinase activity. The 
invariant Lys residue (motif II) is at position 113 
and its mutation abrogates kinase activity. Like its 
homologue, ICP10PK, the HspB8 autokinase 
activity favors Mn2+ions (Smith et al., 2000). 
Physicochemical properties 
Circular dichroism spectroscopy suggests that 
HspB8 is an intrinsically disordered protein (IDP), 
meaning that it does not fold into a stable tertiary 
structure and has a flexible conformation. It 
contains many Pro residues, which enable 
formation of a polyproline type II (PPII) structure 
that contains 2-3 PXXP/PXP repeats. It is rather 
resistant to thermal denaturation and is very 
susceptible to proteolysis, consistent with 
theoretical predictions of disorder probability. 
Ultracentrifugation in glycerol gradients indicates 
that HspB8 is an extended monomer (Chowdary et 
al., 2004), a viewpoint embraced in the 
UniProtKB/Swiss-Prot database. This suggests that 
HspB8 differs from other sHsps that tend to form 
dimers or high-order oligomers. Additional 
properties that distinguish HspB8 from the other 
sHsps include theoretical predictions that its 
structure is enriched in β-strands and unordered 
structures and it lacks the so-called β2 strand seen 
in many other sHsps (reviewed in Mymrikov et al., 
2011). 
Autokinase activity 
HspB8 is an atypical serine/threonine PK that 
resembles the HSV-2 kinase ICP10PK used in its 
cloning. In immunocomplex kinase assays, HspB8 
undergoes autophosphorylation and it 
phosphorylates exogenous protein substrates. 
Specificity is underscored by the finding that 
HspB8 phosphorylates some (viz. myelin basic 
protein), but not other (viz. a-casein or histone IIIS) 
substrates. The definitive proof of intrinsic 
autokinase activity is provided by the loss of 
phosphorylation upon mutation of the invariant Lys 
at position 113, which is required for ATP binding 
(catalytic domain II). This loss of kinase activity is 
not due to a nonspecific conformational alteration, 
because it does not occur upon mutation of the 
adjacent Lys residue at position 115 (Smith et al., 
2000; Aurelian et al., 2001; Depre et al., 2002). 
Further investigations performed on the isolated 
protein confirmed that HspB8 undergoes 
autophosphorylation (Chowdary et al., 2004). The 
rate and extent of phosphorylation are relatively 
low (Kim et al., 2004). However, both are 
significantly increased by mutations that cause 
physichochemical structural change, as exemplified 
by the significantly higher autokinase activity of the 
HspB8 mutant W51C, which has 7 additional β 
turns (Gober et al., 2003; Gober et al., 2004; Gober 
et al., 2005). 
Phosphorylation by other PKs 
Protein kinase C (PKC) phosphorylates HspB8 at 
Ser14 and Thr63, ERK1 at Ser27 and Thr87, and 
casein kinase 2 at a number of unidentified sites 
(Benndorf et al., 2001). cAMP-dependent PK 
phosphorylates HspB8 at Ser57. Phosphorylation of 
Ser57 (S57D) or Ser24 (S24D) or mutation that 
mimics phosphorylation at these sites affects the 
quaternary structure and chaperone-like activity of 
HspB8 (Shemetov et al., 2008). Proteomic studies 
have shown in vivo phosphorylation at Ser24 and 
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Thr87 (Dephoure et al., 2008). However, this may 
be cell type and tissue specific, as phosphorylation 
at Tyr118 was also reported in another tissue 
(Rikova et al., 2007). The conditions that favor the 
distinct phosphorylation patterns and their effect on 
the structure and function of HspB8 are still 
unknown. 
Interactome: sHsps and other proteins and 
affected functions 
HspB8 interacts with most sHsps, but the stability 
and stoichiometry of the complexes are still 
unknown. All methods revealed tight interaction 
with HspB7, but cross-linking and 
immunoprecipitation failed to reveal a tight 
interaction with HSPB1 (Hsp27). Interaction with 
HspB1 and HspB6 is affected by their mutation at 
sites that mimic phosphorylation (Ser15 and Ser16, 
respectively) (Sun et al., 2006). HspB8 mutation at 
position 51 interferes with its ability to interact with 
HspB1 (Smith et al., 2000). The functions regulated 
by HspB8 interaction with the sHsps are largely 
unknown, but interaction with HspB1 appears to 
affect NK activity (reviewed in: Hu et al., 2007; 
Mymrikov et al., 2011; Arrigo, 2013). 
HspB8 also interacts with other proteins. HspB8 
residues 62-133 interact with the RNA-binding 
protein Sam68 that is involved in transportation and 
processing of RNA (Badri et al., 2006). Because 
Sam68 interacts with Src-kinase at an overlapping 
site, its interaction with HspB8 during mitosis may 
indirectly regulate the intracellular localization 
and/or activity of Src-kinase, thereby affecting gene 
expression (transcription/translation). 
Ribonucleoprotein processing is likely affected by 
the interaction between HspB8 and Ddx20 (gemin3, 
Dp120), a protein that has ATP-dependent RNA 
unwinding (helicase) activity and is involved in 
spliceosome assembly and RNA processing (Sun et 
al., 2010). HspB8 also interacts with Destrin 
(DSTN) a cytoskeleton structural and fibrillar 
protein, thereby affecting actin depolymerization. It 
inhibits Rho GTPase and thereby functions in 
tachycardia remodeling, providing a protective 
function. It is suggested that the unique ability of 
HspB8 to inhibit stress fiber formation may be 
connected with its function in autophagy activation, 
which in turn acts as a trigger in RhoA pathway 
initiation (Ke et al., 2011). HspB8 interacts with 
aggregation-associated proteins, such as α 
synuclein, SOD1, TDP-43 and PolyQ, thereby 
inhibiting aggregation or fostering aggregate 
degradation. It is also a Toll-like receptor-4 (TLR-
4) ligand causing dendritic cell activation and 
immunomodulation and it interacts with the 
cytokine-induced apoptosis inhibitor CIAPIN1, but 
the resulting functional modulation is still unclear 
(reviewed in: Arrigo, 2013). Finally, HspB8 binds 
Akt and 5'-AMP-activated PK, thereby promoting 
their nuclear translocation and cell survival (Depre 
et al., 2006), and it interacts with Bag-3 to regulate 
autophagy and with eukaryotic initiation factor 2 
(eIF2) to inhibit translation (Carra, 2009). 
Expression 
Expression in human tissues 
HspB8 is predominantly expressed in human 
skeletal and smooth muscle, heart, and brain. Lower 
expression levels are seen in prostate, placenta, 
lung, kidney, and skin and there is no expression in 
ovaries, testes, liver, pancreas, and spleen (Yu et 
al., 2001). Its expression may be altered in tumor as 
compared to normal tissues (Gober et al., 2003). In 
human skin, HspB8 is expressed in basal 
keratinocytes with long-term in vitro growth 
potential, which are considered the epidermis stem 
cells, and it is required for their proliferation 
(Aurelian et al., 2001). 
Stress-induced expression 
HspB8 has two heat-shock transcription factor- 
(HSF-) binding sites, 1000 bases upstream of the 
translation initiation site. However, its expression is 
not always heat inducible and it can be upregulated 
by diverse stress conditions. For example, HspB8 
expression is not heat-inducible in melanocytes 
(Smith et al., 2011) and it is upregulated by 
sublethal sodium arsenite and oxidative and 
hyperosmotic stress in neurons, where it likely 
contributes protective activity (Bartelt-Kirbach and 
Golenhofen, 2014). 
DNA methylation and the regulation of 
expression/function 
HspB8 differs from other Hsps in that its expression 
in human cells is subject to methylation-associated 
repression. It has a CpG island at the 5'UTR, 216 bp 
upstream of the transcription start site and is 
silenced by aberrant DNA methylation in some 
tumors, notably melanoma, prostate cancer, Ewing's 
sarcoma and hematologic malignancies (viz. 
leukemia, lymphoma). In these tissues/cells, 
restored HspB8 expression has anti-proliferative 
and pro-apoptotic activity (Smith et al,. 2000; 
Gober et al., 2003; Li et al., 2007; Cui et al., 2012). 
However, HspB8 is overexpressed in breast cancer, 
particularly estrogen receptor (ER)+ breast cancer 
and in these cells/tissues, DNA methylation 
contributes to the development of resistance to anti-
estrogen treatment (Fan et al., 2006). High 
throughput cell-based screens recognized 31 
kinases, including HspB8, that confer resistance to 
tamoxifen therapy. They identified HspB8 as the 
expression signature which, by itself, predicts poor 
clinical outcome through inhibition of tamoxifen-
induced autophagy (Gonzalez-Malerva et al., 2011). 
This appears to be facilitated by Lemur tyrosine 
kinase 3 (LMTK3), a serine/threonine kinase which 
functions as a regulator of the ERα and increases 
the levels of HspB8 (Stebbing et al., 2013). The 
mechanisms responsible for the cell type specificity 
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of the HspB8 DNA methylation patterns are still 
unclear. Also unclear is the relationship between 
methylation and accessibility to expression 
regulatory factors, such as HSF or estrogen 
(Charpentier et al., 2000; Sun et al., 2007). 
HspB and co-variant genes in 
differentiation/development 
HspB8 is expressed in the adult mouse and rat 
hippocampus, but expression is modest or absent at 
the embryonic and postnatal stages (Kirbach and 
Golenhofen, 2011). In vitro expression during the 
differentiation of neuronal precursor cells 
confirmed that HspB8 promotes neuronal, but not 
astrocytic differentiation and increases cell survival 
without affecting proliferation. Two groups of 
genes were found to co-vary with HspB8. In the 
positively correlating group, enrichment was seen 
for the categories "regulation of growth" (Hopx, 
Ddr1, Fgfr1, and Ngf) and "regulation of apoptosis" 
(Bag3, Fgfr1, Ngf, and Ticam1). The negatively 
correlating group showed enrichment for the 
categories "intracellular signaling" (Arhgef9, 
Rab14, Rap2a, Gnaq, Plcb1, Gm266, Spred2, and 
Usp8), "apoptosis" (Bcl2l11, Fem1b, and Peg3) and 
"tissue morphogenesis" (Acvr1, Fem1b, and 
Serpinb5). The STRING online database tool 
identified a cluster based around the nerve growth 
factor family, which contained members that 
positively correlate with HspB8, and another cluster 
that was primarily composed of apoptotic proteins 
which interact with the HspB8/Bag-3 complex 
(Ramírez-Rodríguez et al., 2013). 
Localisation 
While it is predominantly detected in the 
cytoplasm, HspB8 also interacts with the plasma 
membrane. In human neuroblastoma SK-N-SH 
cells, it forms tight complexes with phospholipids 
located in the intracellular membrane leaflet. 
HspB8 has two myristoylation motifs (at residues 
62 and 132) and one N-glycosylation motif that 
likely facilitate membrane-binding and surface 
localization. It also co-localizes with cell surface 
aggregates formed by partially denatured or 
improperly folded proteins, for example in 
Alzheimer's or Huntington disease. Unlike other 
Hsps, it does not always translocate to the nucleus 
upon heat shock stress. This is likely due to leucine-
rich nuclear export signal (NES) motifs that favor 
cytosolic localization and are located at the N- 
(residues 21-31) and C- (residues 157-166) termini 
(Smith et al., 2000; Aurelian et al., 2001; Yu et al., 
2001; Gober et al., 2003; Gober et al., 2004; 
Chowdary et al., 2007). 
Function 
Chaperone activity 
HspB8 overexpression prevents the formation of 
aggregosomes containing desmin and the R120G 
mutant of αB-crystallin (HspB5) that correlate with 
the development of desmin-related cardiomyopathy 
and improve cardiac function (Chowdary et al., 
2004; Kim et al., 2006; Sanbe et al., 2009). HspB8 
also interacts with the αB-crystallin mutants Q151X 
and 464delCT that form aggregates associated with 
the development of myofibrillar myopathy (Simon 
et al., 2007), and amyloid β-peptides (Aβ1-42 and 
Aβ1-40), thereby reducing the accumulation of 
amyloid peptides on the cell surface and inhibiting 
the death of cardiovascular cells induced by Dutch-
type Aβ1-40 (Wilhelmus et al., 2006). It prevents in 
vivo aggregation of polyglutamine containing 
proteins, such as a fragment of huntingtin that 
contains 43 Gln and the androgen receptor that 
contains 65 Gln residues (Wilhelmus et al., 2006; 
Rusmini et al., 2013) and it is upregulated in 
neurons exposed to sublethal sodium arsenite or 
oxidative and hyperosmotic stress, contributing 
chaperone-related protection (Bartelt-Kirbach and 
Golenhofen, 2014). Quantitation of the in vitro 
chaperone-like activity of HspB8 using model 
substrates and size exclusion chromatography 
showed that HspB8 undergoes dynamic molecular 
transition in solution, existing in a dynamic 
equilibrium between various oligomers; 
predominantly octamers in a nonphysiological 
solution and mainly tetramers in a physiological 
solution (pH 7.4) (Yang et al., 2012). 
The Lys141 residue in the HspB8 α-crystallin motif 
is a mutational hot spot for the development of 
peripheral neuropathy. Two natural missense 
mutations, K141E and K141N, were associated 
with distal hereditary motor neuropathy type II 
(dHMN) and autosomal dominant Charcot-Marie-
Tooth disease type 2L (CMT2L) in a large Chinese 
family (Irobi et al., 2004; Tang et al., 2005) and 
another mutation, K141T, was described in a 
Korean patient with Charcot-Marie-Tooth disease 
(Nakhro et al., 2013). The mutants cause neurite 
degeneration in motor but not sensory and cortical 
neurons (Irobi et al., 2010), which is apparently 
related to decreased chaperone-like activity 
measured on polyglutamine proteins as in vivo 
substrates (Carra et al., 2005). Ddx20 mutants fail 
to interact with HspB8, potentially causing different 
forms of inherited motor neuron diseases (Sun et 
al., 2010), but K141N can also cause 
cardiomyopathy, which is associated with the 
formation of perinuclear HspB8-positive aggregates 
that contain amyloid oligomer intermediates (Sanbe 
et al., 2013). 
Inhibition of unfolded protein response (UPR) 
HspB8 contributes to the proteolytic degradation of 
unfolded proteins, involving proteosomes or 
autophagy regulation. By affecting proteosome 
stability and intracellular localization, HspB8 
induces the degradation of proteins, such as Foxo3 
that prevent cardiac hypertrophy under normal 
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conditions (Hedhli et al., 2008). By interacting with 
the co-chaperone Bag-3 at the hydrophobic pocket 
formed by the β4- and β8-strands, it forms a 
complex with a 1:2 stoichiometry of Bag-3 to 
HspB8 (Fuchs et al., 2009) that fosters interaction 
with Hsc70, thereby giving rise to the 
multiheteromeric chaperone-assisted selective 
autophagy (CASA) complex. Together with the 
chaperone-associated ubiquitin ligase CHIP, this 
complex functions to remove misfolded proteins. It 
enables the ubiquitylation of the mutant superoxide 
dismutase (mSOD1) protein that is implicated in 
the development of amyotrophic lateral sclerosis 
(ALS), promoting its autophagic removal (Crippa et 
al., 2010a; Crippa et al., 2010b; Rosati et al., 2011; 
Vos et al., 2011). HspB8/Bag-3 interaction also has 
an important role in the protection of astrocytes 
against different protein aggregation diseases, 
apparently through autophagy-related aggregate 
clearance (Seidel et al., 2012) and it may contribute 
to chaperone-assisted selective autophagy in limb-
girdle muscular dystrophy type 1D (LGMD1D), a 
myopathy caused by mutations of the Hsp40 family 
member DNAJB6 (Sato et al., 2013). During 
recovery from heat shock, the transcription factor 
nuclear factor-kappa B (NF-κB) activates selective 
removal of misfolded or aggregated proteins by 
controlling the expression of HspB8 and Bag-3 and 
increasing HspB8/Bag-3 complex formation, 
thereby increasing cell survival (Nivon et al., 2012). 
The CASA complex is also involved in mechanical 
tension, a physiological stimulus required for the 
development and homeostasis of locomotory, 
cardiovascular, respiratory, and urogenital systems 
and it contributes to stem cell differentiation, 
immune cell recruitment, and tumorigenesis. It 
senses the mechanical unfolding of the actin-
crosslinking protein filamin, and together with 
CHIP, it initiates the ubiquitin-dependent 
autophagic sorting of damaged filamin to 
lysosomes for degradation (Ulbricht et al., 2013). 
HspB8 is also involved in spinal and bulbar 
muscular atrophy (SBMA), which is an X-linked 
neuromuscular disease characterized by the loss of 
motoneurons in the spinal cord and bulbar regions 
of the brain stem. Here, neuronal toxicity results 
from protein misfolding and aggregation of 
androgen receptor mutants that contain an 
elongated N-terminal polyglutamine tract 
(ARpolyQ) and are apparently dependent on 
autophagic flux failure. HspB8 restores the normal 
autophagic flux in motoneurons expressing 
ARpolyQ by exerting anti-aggregation and/or pro-
degradative activity on ARpolyQ (Rusmini et al., 
2013). Finally, HspB8 is upregulated in rat models 
of diabetes mellitus, where it is believed to play a 
key role in recovery and the prevention of disease-
associated complications (Karthik et al., 2012; 
Reddy et al., 2013). However, studies of mSOD1 
transgenic animals have shown that the HspB8-
dependent autophagic response is much higher in 
muscle than spinal cord, potentially identifying a 
mechanism other than degradation of misfolded 
proteins (Crippa et al., 2013). Indeed, the 
HspB8/Bag-3 complex can activate 
phosphorylation of the α-subunit of the translation 
initiator factor eIF2, resulting in the general 
inhibition of protein synthesis and stimulating 
autophagy, independent of Hsc70 (Carra, 2009; 
Carra et al., 2009). 
Signaling: stem cells, cancer and apoptosis 
HspB8 has both pro- and anti-proliferative (pro-
apoptotic) activity and it is cell type specific. 
Proliferative activity was seen in stem cells and in 
some cancers. For example, in human skin, HspB8 
is expressed in basal keratinocytes with stem cell 
potential and is required for their proliferation 
(Aurelian et al., 2001). HspB8 is also expressed in 
breast cancer, glioblastoma, stomach tumors and rat 
pheochromocytoma (PC12) cells (Gober et al., 
2005) and its expression is further increased in 
breast cancer cells treated with 17- β estradiol 
(Yang et al., 2006). In these tumors HspB8 
demonstrates proliferative and anti-apoptotic 
properties. In breast cancer and glioblastoma cells, 
HspB8 functions in cell cycle regulation to prevent 
apoptosis, potentially through activation of the 
growth-associated transcription factor E2f and the 
cyclin-dependent kinase cdk4. HspB8 might also 
regulate expression of Sam68 thereby modulating 
the proliferative potential of the glioblastoma cells 
(Modem et al., 2011). Analysis of tissues from 
patients with breast ductal carcinoma in situ and 
invasive ductal carcinoma compared to normal 
matched controls, confirmed increased expression 
of HspB8 in invasive lesions, and showed that 
HspB8 induces anchorage independence and 
increases cell proliferation (Yang et al., 2006). 
Moreover, HspB8 overexpression was shown to 
increase radiation sensitivity, whereas its inhibition 
with siRNA was accompanied by decreased 
radiation sensitivity (Trent et al., 2007). In 
melanoma and cervical cancer, HspB8 mutation has 
been associated with sustained expression and the 
acquisition of proliferative anti-apoptotic activity as 
evidenced by the W51C mutant that has dominant 
cytoprotective activity and blocks apoptosis 
induced by wild type HspB8. The W51C 
cytoprotective activity is through activation of the 
B-Raf/ERK1/ERK2 survival pathway and it is 
associated with a 5-6-fold higher autokinase 
activity than that of the wild type protein (Gober et 
al., 2003). 
By contrast, HspB8 has pro-apoptotic activity in 
other tumor cells. It's expression is reduced in 
melanoma, prostate cancer, Ewing's sarcoma and 
hematologic malignancies through aberrant DNA 
methylation. The levels of inhibition strongly 
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correlate with those of DNA methylation (p < .001), 
suggesting that HspB8 may serve as a marker for 
de-methylating therapeutics (Smith et al., 2011). In 
these tumors, restored HspB8 expression induces 
cell death and inhibits tumor growth in xenograft 
models (Gober et al., 2003; Gober et al., 2005; Li et 
al., 2007; Cui et al., 2012). HspB8-induced 
melanoma cell death is through the activation of 
line-specific death pathways that culminate in 
apoptosis and initiate with the activation of the 
MAP3K family member TGF-beta-activated kinase 
1 (TAK1). In some of the tumor lines/xenografts, 
apoptosis is caused by the activation of the 
TAK1/p38MAPK/caspase-3/caspase-7 pathway. In 
others, apoptosis is through the activation of novel 
TAK1-dependent signaling pathways. These 
include (i) ASC-mediated caspase-1 activation 
independent of the inflammasome, (ii) Beclin-1 
upregulation through mTOR phosphorylation at 
S2481 which is the site of intrinsic mTORC1-
specific catalytic activity, and (iii) apoptosis caused 
by caspase-1-mediated Beclin-1 cleavage and its 
translocation to the mitochondria (see attached 
diagram below). These findings identify HspB8 as a 
regulator of TAK1 and mTORC1 pathways that 
function independent of Akt and involve 
inflammation-unrelated caspase-1 mediated 
modulation of the haploinsufficient tumor 
suppressor Beclin-1 (Smith et al., 2012). 
Signaling: cardiac cell hypertrophy and survival 
HspB8 expression is increased in transient 
ischemia, likely indicating its involvement in cell 
survival (Depre et al., 2001), and it has a protective 
role in reversible, but not irreversible myocardial 
injury (Depre et al., 2004). Transgenic mice with a 
7-fold increase in HspB8 expression evidence 
significant myocardial hypertrophy accompanied by 
activation of Akt and p70S6 kinase (Depre et al., 
2002). These mice are characterized by increased 
expression of glucose transporter GLUT1 in the 
myocytes plasma membrane, as well as increased 
glycogen content and phosphoglucomutase activity 
in the heart, suggesting that HspB8 functions in the 
cardiac adaptation to stress by coordinating cell 
growth, survival, and metabolism (Wang et al., 
2004). Cell survival in this system is due to anti-
apoptotic activity resulting from the direct 
interaction of HspB8 with Akt (Hase et al., 2005). 
In addition, HspB8 has metabolic and survival 
properties that seem to be due to direct interaction 
and activation of AMP-dependent protein kinase, 
which is responsible for increased translocation of 
GLUT1 to the plasma membrane and increased 
myocardial glycogen content (Depre et al., 2006; 
Danan et al., 2007). In transgenic mice with 
cardiac-specific HspB8 overexpression, HspB8 
activates the "canonical" bone morphogenetic 
protein (BMP) pathway, where interaction of BMP 
with its receptors (BMPR-II) and Alk3 results in 
Smad1/Smad5/Smad8 phosphorylation. HspB8 also 
activates the "noncanonical" BMP pathway, 
promoting activation of TAK1/PI3-K/Akt and 
TAK1 interaction with Alk3 and BMPR-II (Sui et 
al., 2009). Myocardial hypertrophy results from 
HspB8-mediated activation of the PI3-K/Akt 
pathway independent of its autokinase activity 
(Depre et al., 2002; Sui et al., 2009). However, high 
dose HspB8 induces autokinase-dependent 
apoptosis through the inhibition of casein kinase 2 
activity (Hase et al., 2005). HspB8 upregulation by 
ischemia/reperfusion provides cardioprotection 
through enhanced mitochondrial production of 
nitric oxide (NO), which stimulates oxidative 
phosphorylation in normoxia and decreases 
oxidative phosphorylation and reactive oxygen 
species production after anoxia. The upregulation of 
HspB8 is correlated with increased expression of 
the inducible isoform of nitric oxide synthase 
(Laure et al., 2012). HspB8 deletion decreases the 
phosphorylation of the transcription factor, STAT3, 
impairs transactivation of the stress response genes 
regulated by STAT3, and causes a significant 
decrease in both mitochondrial STAT3 
translocation and respiration. In addition, HspB8 
deletion interferes with the activation of cell 
survival pathways, including Akt, ERK, and iNOS 
(Qiu et al., 2011). In rats with induced myocardial 
infarction the mitochondrial translocation of HspB8 
is reduced, potentially contributing to the impaired 
mitochondrial energy-producing ability that leads to 
heart failure after a myocardial infarction 
(Marunouchi et al., 2013). 
Tumor suppressor 
HspB8 has tumor suppressor activity. It is 
expressed in human melanocytes, where it 
functions as a cell cycle regulator and causes 
growth arrest through β-catenin phosphorylation at 
the transcriptional activity site Ser(552) and 
inhibition of the cell-cycle regulatory proteins 
cyclin E/Cdk2 that control G1 to S transition (Smith 
et al., 2011).  
In melanoma and other cancers, its expression is 
inhibited through aberrant DNA methylation and 
restored expression through treatment with de-
methylating agents causes cell death and inhibits 
tumor growth (Li et al., 2007; Smith et al., 2012; 
Cui et al., 2012). Tumor cell death is through the 
activation of death pathways that lead to apoptosis 
and activation of additional tumor suppressor 
functions that include the haploinsufficient tumor 
suppressor Beclin-1 (Smith et al., 2012). 
Supporting the interpretation that HspB8 has tumor 
suppressor function is the finding that it is highly 
expressed in glioblastoma cells, where its inhibition 
is associated with increased cell proliferation 
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Schematic representation of the death pathways induced by HspB8 in different cells. A2058 and A375 are melanoma cells in 
which HspB8 signals through distinct pathways to cause cell death. While both pathways initiate with TAK1 activation, the 
contribution of p38MAPK and the caspases differs. In A375 cells, the TAK1/p38MAPK pathway activates caspases 3 and 7 to 
cause apoptosis. In A2058 cells, the TAK1/p38MAPK pathway activates caspase-3, but TAK1 also activates caspase-1 through 
ASC upregulation and upregulates Beclin-1 through mTOR phosphorylation at S2481. Caspase-1 cleaves Beclin-1 to promote 
apoptosis, but Beclin-1 also contributes to cell death through still unknown tumor suppressor functions. In both cell types, the 
HspB8 mutant W51C has dominant proliferative potential through its ability to trigger a B-Raf/ERK survival pathway that appears 
to be dependent on autokinase activity. 
 
The cell-cycle regulatory potential of HspB8 in 
normal cells, its dysfunctional state in cancer cells, 
and its ability to induce tumor cell death, identify 
HspB8 as a tumor suppressor. Also characteristic of 
tumor suppressors, such as p53, is the cell-type 
specificity of the HspB8 effects and the finding that 
it can undergo single-site mutation to lose its 
activity or to acquire neoplastic potential. This is 
respectively exemplified by the natural mutants 
P173H, which is inactive, and W51C, which has 
proliferative (anti-apoptotic) activity (Gober et al., 
2003; Smith et al., 2011; Smith et al., 2012). 
However, the frequency of such naturally occurring 
mutations is still unknown. 
Inflammation and autoimmunity 
HspB8 activates antigen-presenting dendritic cells 
through a TLR-4-dependent pathway and it is 
abundantly expressed in synovial tissues from 
patients with rheumatoid arthritis, potentially 
contributing to autoimmunity (Roelofs et al., 2006). 
It also induces interleukin-6 (IL-6) production in 
cultured pericytes and astrocytes, potentially 
contributing to local inflammation in Dutch type 
amyloidosis (Wilhelmus et al., 2009). HspB8 is 
upregulated in synovial fibroblasts exposed to 5% 
cigarette smoke extract and in synovial tissues of 
smokers with rheumatoid arthritis (RA), suggesting 
that it activates signaling pathways which promote 
the development of autoimmunity and chronic joint 
inflammation (Ospelt et al., 2014). Astrocytes are 
key players in driving CNS inflammation. They 
respond to insult with a process of cellular 
activation known as reactive astrogliosis, a key 
signal of which is activated NF-κB that drives CNS 
inflammation (Brambilla et al., 2014). Examination 
of post-mortem brain tissues from patients with 
protein conformation disorders, such as Alzheimer's 
disease, Parkinson's disease, Huntington's disease, 
and spinocerebellar ataxia type 3 (SCA3), revealed 
a strong upregulation of HspB8 and a moderate 
upregulation of Bag-3 in astrocytes in the cerebral 
areas affected by neuronal damage and 
degeneration. This was not the case for neurons, 
irrespective of their localization or the presence of 
protein aggregates. These findings were interpreted 
to suggest that the HspB8/Bag-3 complex enhances 
the ability of astrocytes to clear aggregated proteins 
released from neurons in order to maintain local 
tissue homeostasis and/or modulate the 
inflammatory response during astrogliosis (Seidel 
et al., 2012). The ability of HspB8 to regulate 
inflammatory responses is further supported by our 
finding that restored HspB8 expression in 
melanoma cells induces TAK1-dependent 
activation of receptor-interacting protein 2 kinase 
(RIP-2) that activates NF-κB and results in 
increased production of the pro-inflammatory 
cytokine TNF-α. 
Homology 
HspB8 has 32% identity and 59% homology with 
the HSV-2 gene ICP10PK that was used for its 
cloning (Gober et al., 2005). This level of sequence 
homology is similar to that seen for viral Bcl-2 
homologues and their cellular counterparts, 
supporting the interpretation that the two proteins 
HSPB8 (heat shock 22kDa protein 8) Bollino D, Aurelian L 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12) 914 
are members of the same family. HspB8 and 
ICP10PK share multifunctional activities that 
encompass signaling, UPR, inflammatory 
responses, and the regulation of life-cycle potential. 
The contribution that ICP10PK molecular mimicry 
may have towards the ability of HspB8 to 
contribute to the development of autoimmune 
disorders is still unknown (Aurelian et al., 2012). 
However, if we accept the premise that the presence 
of an α-crystallin motif, even if degenerate, is a sine 
qua non criterion for evolutionary-based inclusion 
into the sHsp family, we must infer that ICP10PK is 
evolutionarily related to HspB8. According to this 
interpretation, ICP10PK is likely to have evolved 
from HspB8, which was originally captured by 
HSV-2 in order to provide survival advantages such 
as the inhibition of neuronal apoptosis that is 
required for virus growth and latency reactivation 
(Aurelian et al., 2012). Presumably, once it was 
captured and fused in-frame with the viral R1, 
HspB8 fell under the control of the R1 promoter, 
losing the regulatory constraints that define its cell-
type-specific death-inducing potential while 
retaining kinase and ATPase-independent 
chaperone activity and the ability to inhibit UPR. 
This interpretation is supported by the recent 
finding of chimeric genes that consist of in-frame 
fused genes captured from different sources. Also 
consistent with this interpretation are the restriction 
of the homology to HSV-2, but not the closely 
related virus HSV-1, and the presence of missense 
mutations that convert HspB8 from a pro-apoptotic 
to a dominant anti-apoptotic protein. This 
interpretation is in line with current understanding 
of virus evolution, which recognizes viruses as 
"gene robbers" that have evolved after cellular 
species (Holmes, 2011). However, ICP10PK differs 
from HspB8 in that it has a transmembrane domain 
that is required for its kinase activity, and the 
possibility cannot be excluded that HspB8 evolved 
from ICP10PK captured by the cell from HSV-2 for 
an anti-stress function. Indeed, it is becoming 
increasingly evident that virus sequences can be 
incorporated into the germ-line DNA of the host, 
becoming inherited alongside the host sequences 
and contributing significant functions (Weiss and 
Stoye, 2013). 
Mutations 
Germinal 
Three naturally occurring missense mutations, 
K141E, K141N, and K141T, located in the α-
crystallin domain of HspB8 result in decreased 
chaperone-like activity and impaired clearance of 
aggregated proteins. Their expression has been 
implicated in the development of Charcot-Marie-
Tooth disease type 2L and distal hereditary motor 
neuropathy (Nakhro et al., 2013).  
Mutations of unknown origin: The naturally 
occurring mutation W51C, results in a protein with 
7 additional β turns and significantly higher 
autokinase activity. The W51C mutation converts 
HspB8 from a pro-apoptotic to a dominant anti-
apoptotic protein that induces cell proliferation 
through the B-Raf/ERK pathway independent of the 
cell type. In both W51C and another naturally 
occurring mutation, P173H, TAK-1 and its 
downstream pro-apoptotic pathways are not 
activated (Gober et al., 2003). 
Mutations not occurring in nature include S24D, 
S27D, and T87D, which interfere with the 
phosphorylation of HspB8. The S159D mutation 
has no effect on phosphorylation (Shemetov et al., 
2011). 
Somatic 
Unknown. 
Implicated in 
Melanoma and other cancers 
Note 
HspB8 is expressed in normal melanocytes, where 
it causes growth arrest through β-catenin 
phosphorylation at the transcriptional activity site 
Ser (552) and inhibition of the Cyclin E/Cdk2 
complex.  
Like the established tumor suppressors, it is 
silenced by aberrant DNA methylation in most 
melanoma tissues and in other cancers (e.g. prostate 
cancer, Ewing's sarcoma, and hematologic 
malignancies), and its restored expression induces 
cell death (Gober et al., 2003; Gober et al., 2005; Li 
et al., 2007; Cui et al., 2012). Tumor cell death is 
through the activation of death pathways that lead 
to apoptosis as well as the activation of additional 
tumor suppressor functions, including upregulation 
of the haploinsufficient tumor suppressor Beclin-1 
(Smith et al., 2012). The role of HspB8 as a tumor 
suppressor is further supported by the finding of a 
pro-tumorigenic mutation associated with increased 
autokinase activity (W51C). This mutation 
indicates that the autokinase activity is required for 
the HspB8 proliferative, but not anti-proliferative 
(pro-apoptotic) activity (Gober et al., 2003; Smith 
et al., 2011; Smith et al., 2012). 
Charcot-Marie-Tooth disease type 2L 
(CMT2L) 
Note 
CMT is an inherited peripheral nerve disorder 
divided into two types: the demyelinating form 
(CMT1) and the axonal defective form (CMT2). 
Three nonsynonymous mutations of the same 
Lys141 residue (K141E, K141T, K141N) in HspB8 
are implicated in CMT2. The lysine residue is 
located in the highly conserved α-crystallin domain, 
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and mutations in this region interfere with 
chaperone activity (Nakhro et al., 2013). 
Distal hereditary motor neuropathy 
(DHMN) 
Note 
DHMN is a motor disorder of the peripheral 
nervous system that results in atrophy and muscle 
wasting.  
Two naturally occurring missense mutations, 
K141N and K141E, in the α-crystallin domain have 
been implicated in DHMN. These mutants cause 
neurite degeneration in motor but not sensory and 
cortical neurons (Irobi et al., 2010), which is 
apparently related to decreased chaperone-like 
activity measured on polyglutamine proteins as in 
vivo substrates (Carra et al., 2005). 
Spinal and bulbar muscular atrophy 
(SBMA) 
Note 
SBMA is an X-linked neuromuscular disease 
characterized by the loss of motoneurons in the 
spinal cord and bulbar regions of the brain stem. 
Neuronal toxicity results from protein misfolding 
and aggregation of androgen receptor mutants that 
contain an elongated N-terminal polyglutamine 
tract (ARpolyQ) and is apparently dependent on 
autophagic flux failure. HspB8 restores the normal 
autophagic flux in motoneurons expressing 
ARpolyQ by exerting anti-aggregation and/or pro-
degradative activity on ARpolyQ (Rusmini et al., 
2013). 
Limb-girdle muscular dystrophy type 
1D (LGM1D) 
Note 
LGMD1D is a form of muscular dystrophy 
characterized by proximal dominant muscle 
weakness and atrophy and caused by mutations of 
the Hsp40 family member DNAJB6. 
Immunohistochemical analysis revealed co-
accumulation of HspB8 and members of the 
chaperone-assisted selective autophagy complex 
with DNAJB6 in cytoplasmic inclusions (Sato et 
al., 2013). 
Alzheimers 
Note 
HspB8 is associated with the senile plaques of 
Alzheimer's disease patients and the cerebral 
amyloid angiopathy of patients with hereditary 
cerebral hemorrhage with amyloidosis of the Dutch 
type (HCHWA-D), and was shown to directly 
interact with amyloid-β peptide. HspB8 likely 
functions in maintaining the balance between 
production and clearance of amyloid-β, as well as 
its aggregation (Wilhelmus et al., 2006). 
Amyotrophic lateral sclerosis (ALS) 
Note 
ALS is a neurodegenerative disorder characterized 
by the accumulation of misfolded proteins. Some 
familial forms of the disorder have been linked to 
mutations in the superoxide dismutase 1 (SOD1) 
gene.  
Mutant SOD1 proteins misfold and form 
aggregates, which impair proteasomal activity. 
HspB8 has been shown to bind and assist in the 
clearance of mutant SOD1 aggregates through 
autophagy (Crippa et al., 2010b). 
Heart failure 
Note 
Expression of HspB8 is induced by cardiac 
overload. When exposed to pressure overload, mice 
with a HspB8 deletion experience a faster transition 
into heart failure and increased mortality compared 
to wild type controls.  
HspB8 deletion decreases the phosphorylation of 
the transcription factor, STAT3, impairs 
transactivation of the stress response genes 
regulated by STAT3, and causes a significant 
decrease in both mitochondrial STAT3 
translocation and respiration. In addition, HspB8 
deletion interferes with the activation of cell 
survival pathways, including Akt, ERK, and iNOS 
(Qiu et al., 2011). 
Diabetes 
Note 
In a rat model of diabetes mellitus, increased levels 
of HspB8 have been observed in the blood plasma, 
where it is believed to play a key role in recovery 
and the prevention of disease-associated 
complications (Karthik et al., 2012).  
Upregulation of HspB8, as well as other Hsps, has 
also been seen in the diabetic retina, implicating it 
in the protection of retinal neurons and prevention 
of diabetic retinopathy (Reddy et al., 2013). 
References 
Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, 
Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM. Effects of 
estrogen on global gene expression: identification of novel 
targets of estrogen action. Cancer Res. 2000 Nov 
1;60(21):5977-83 
Smith CC, Yu YX, Kulka M, Aurelian L. A novel human 
gene similar to the protein kinase (PK) coding domain of 
the large subunit of herpes simplex virus type 2 
ribonucleotide reductase (ICP10) codes for a serine-
threonine PK and is expressed in melanoma cells. J Biol 
Chem. 2000 Aug 18;275(33):25690-9 
Aurelian L, Smith CC, Winchurch R, Kulka M, Gyotoku T, 
Zaccaro L, Chrest FJ, Burnett JW. A novel gene expressed 
in human keratinocytes with long-term in vitro growth 
potential is required for cell growth. J Invest Dermatol. 
2001 Feb;116(2):286-95 
 
HSPB8 (heat shock 22kDa protein 8) Bollino D, Aurelian L 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12) 916 
Benndorf R, Sun X, Gilmont RR, Biederman KJ, Molloy 
MP, Goodmurphy CW, Cheng H, Andrews PC, Welsh MJ. 
HSP22, a new member of the small heat shock protein 
superfamily, interacts with mimic of phosphorylated HSP27 
((3D)HSP27). J Biol Chem. 2001 Jul 20;276(29):26753-61 
Depre C, Tomlinson JE, Kudej RK, Gaussin V, Thompson 
E, Kim SJ, Vatner DE, Topper JN, Vatner SF. Gene 
program for cardiac cell survival induced by transient 
ischemia in conscious pigs. Proc Natl Acad Sci U S A. 
2001 Jul 31;98(16):9336-41 
Yu YX, Heller A, Liehr T, Smith CC, Aurelian L. Expression 
analysis and chromosome location of a novel gene (H11) 
associated with the growth of human melanoma cells. Int J 
Oncol. 2001 May;18(5):905-11 
Depre C, Hase M, Gaussin V, Zajac A, Wang L, Hittinger 
L, Ghaleh B, Yu X, Kudej RK, Wagner T, Sadoshima J, 
Vatner SF. H11 kinase is a novel mediator of myocardial 
hypertrophy in vivo. Circ Res. 2002 Nov 29;91(11):1007-14 
Gober MD, Smith CC, Ueda K, Toretsky JA, Aurelian L. 
Forced expression of the H11 heat shock protein can be 
regulated by DNA methylation and trigger apoptosis in 
human cells. J Biol Chem. 2003 Sep 26;278(39):37600-9 
Kappé G, Franck E, Verschuure P, Boelens WC, 
Leunissen JA, de Jong WW. The human genome encodes 
10 alpha-crystallin-related small heat shock proteins: 
HspB1-10. Cell Stress Chaperones. 2003 Spring;8(1):53-
61 
Chowdary TK, Raman B, Ramakrishna T, Rao CM. 
Mammalian Hsp22 is a heat-inducible small heat-shock 
protein with chaperone-like activity. Biochem J. 2004 Jul 
15;381(Pt 2):379-87 
Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper 
JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, 
Camici PG, Vatner SF. Program of cell survival underlying 
human and experimental hibernating myocardium. Circ 
Res. 2004 Aug 20;95(4):433-40 
Gober MD, Depre C, Aurelian L. Correspondence 
regarding M.V. Kim et al. "Some properties of human small 
heat shock protein Hsp22 (H11 or HspB8)". Biochem 
Biophys Res Commun. 2004 Aug 20;321(2):267-8 
Irobi J, Van Impe K, Seeman P, Jordanova A, Dierick I, 
Verpoorten N, Michalik A, De Vriendt E, Jacobs A, Van 
Gerwen V, Vennekens K, Mazanec R, Tournev I, Hilton-
Jones D, Talbot K, Kremensky I, Van Den Bosch L, 
Robberecht W, Van Vandekerckhove J, Van Broeckhoven 
C, Gettemans J, De Jonghe P, Timmerman V. Hot-spot 
residue in small heat-shock protein 22 causes distal motor 
neuropathy. Nat Genet. 2004 Jun;36(6):597-601 
Kim MV, Seit-Nebi AS, Marston SB, Gusev NB. Some 
properties of human small heat shock protein Hsp22 (H11 
or HspB8). Biochem Biophys Res Commun. 2004 Mar 
19;315(4):796-801 
Wang L, Zajac A, Hedhli N, Depre C. Increased expression 
of H11 kinase stimulates glycogen synthesis in the heart. 
Mol Cell Biochem. 2004 Oct;265(1-2):71-8 
Carra S, Sivilotti M, Chávez Zobel AT, Lambert H, Landry 
J. HspB8, a small heat shock protein mutated in human 
neuromuscular disorders, has in vivo chaperone activity in 
cultured cells. Hum Mol Genet. 2005 Jun 15;14(12):1659-
69 
Fontaine JM, Sun X, Benndorf R, Welsh MJ. Interactions 
of HSP22 (HSPB8) with HSP20, alphaB-crystallin, and 
HSPB3. Biochem Biophys Res Commun. 2005 Nov 
25;337(3):1006-11 
Gober MD, Wales SQ, Aurelian L. Herpes simplex virus 
type 2 encodes a heat shock protein homologue with 
apoptosis regulatory functions. Front Biosci. 2005 Sep 
1;10:2788-803 
Hase M, Depre C, Vatner SF, Sadoshima J. H11 has 
dose-dependent and dual hypertrophic and proapoptotic 
functions in cardiac myocytes. Biochem J. 2005 Jun 
1;388(Pt 2):475-83 
Tang BS, Zhao GH, Luo W, Xia K, Cai F, Pan Q, Zhang 
RX, Zhang FF, Liu XM, Chen B, Zhang C, Shen L, Jiang 
H, Long ZG, Dai HP. Small heat-shock protein 22 mutated 
in autosomal dominant Charcot-Marie-Tooth disease type 
2L. Hum Genet. 2005 Feb;116(3):222-4 
Villeneuve J, Tremblay P, Vallières L. Tumor necrosis 
factor reduces brain tumor growth by enhancing 
macrophage recruitment and microcyst formation. Cancer 
Res. 2005 May 1;65(9):3928-36 
Badri KR, Modem S, Gerard HC, Khan I, Bagchi M, 
Hudson AP, Reddy TR. Regulation of Sam68 activity by 
small heat shock protein 22. J Cell Biochem. 2006 Dec 
1;99(5):1353-62 
Depre C, Wang L, Sui X, Qiu H, Hong C, Hedhli N, Ginion 
A, Shah A, Pelat M, Bertrand L, Wagner T, Gaussin V, 
Vatner SF. H11 kinase prevents myocardial infarction by 
preemptive preconditioning of the heart. Circ Res. 2006 
Feb 3;98(2):280-8 
Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer 
SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, 
Nephew KP. Diverse gene expression and DNA 
methylation profiles correlate with differential adaptation of 
breast cancer cells to the antiestrogens tamoxifen and 
fulvestrant. Cancer Res. 2006 Dec 15;66(24):11954-66 
Kim MV, Kasakov AS, Seit-Nebi AS, Marston SB, Gusev 
NB. Structure and properties of K141E mutant of small 
heat shock protein HSP22 (HspB8, H11) that is expressed 
in human neuromuscular disorders. Arch Biochem 
Biophys. 2006 Oct 1;454(1):32-41 
Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz 
S, Geurts J, Wunderink LU, Schreurs BW, van den Berg 
WB, Radstake TR. Identification of small heat shock 
protein B8 (HSP22) as a novel TLR4 ligand and potential 
involvement in the pathogenesis of rheumatoid arthritis. J 
Immunol. 2006 Jun 1;176(11):7021-7 
Sun X, Welsh MJ, Benndorf R. Conformational changes 
resulting from pseudophosphorylation of mammalian small 
heat shock proteins--a two-hybrid study. Cell Stress 
Chaperones. 2006 Spring;11(1):61-70 
Wilhelmus MM, Boelens WC, Otte-Höller I, Kamps B, 
Kusters B, Maat-Schieman ML, de Waal RM, Verbeek MM. 
Small heat shock protein HspB8: its distribution in 
Alzheimer's disease brains and its inhibition of amyloid-
beta protein aggregation and cerebrovascular amyloid-
beta toxicity. Acta Neuropathol. 2006 Feb;111(2):139-49 
Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi 
D, Schmidt EV. Identification of cyclin D1- and estrogen-
regulated genes contributing to breast carcinogenesis and 
progression. Cancer Res. 2006 Dec 15;66(24):11649-58 
Chowdary TK, Raman B, Ramakrishna T, Rao ChM. 
Interaction of mammalian Hsp22 with lipid membranes. 
Biochem J. 2007 Jan 15;401(2):437-45 
Danan IJ, Rashed ER, Depre C. Therapeutic potential of 
H11 kinase for the ischemic heart. Cardiovasc Drug Rev. 
2007 Spring;25(1):14-29 
HSPB8 (heat shock 22kDa protein 8) Bollino D, Aurelian L 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12) 917 
Hu Z, Chen L, Zhang J, Li T, Tang J, Xu N, Wang X. 
Structure, function, property, and role in neurologic 
diseases and other diseases of the sHsp22. J Neurosci 
Res. 2007 Aug 1;85(10):2071-9 
Li B, Smith CC, Laing JM, Gober MD, Liu L, Aurelian L. 
Overload of the heat-shock protein H11/HspB8 triggers 
melanoma cell apoptosis through activation of transforming 
growth factor-beta-activated kinase 1. Oncogene. 2007 
May 24;26(24):3521-31 
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, 
Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, 
Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan 
J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, 
Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb 
MJ. Global survey of phosphotyrosine signaling identifies 
oncogenic kinases in lung cancer. Cell. 2007 Dec 
14;131(6):1190-203 
Simon S, Fontaine JM, Martin JL, Sun X, Hoppe AD, 
Welsh MJ, Benndorf R, Vicart P. Myopathy-associated 
alphaB-crystallin mutants: abnormal phosphorylation, 
intracellular location, and interactions with other small heat 
shock proteins. J Biol Chem. 2007 Nov 23;282(47):34276-
87 
Sun X, Fontaine JM, Bartl I, Behnam B, Welsh MJ, 
Benndorf R. Induction of Hsp22 (HspB8) by estrogen and 
the metalloestrogen cadmium in estrogen receptor-positive 
breast cancer cells. Cell Stress Chaperones. 2007 
Winter;12(4):307-19 
Trent S, Yang C, Li C, Lynch M, Schmidt EV. Heat shock 
protein B8, a cyclin-dependent kinase-independent cyclin 
D1 target gene, contributes to its effects on radiation 
sensitivity. Cancer Res. 2007 Nov 15;67(22):10774-81 
Villén J, Beausoleil SA, Gerber SA, Gygi SP. Large-scale 
phosphorylation analysis of mouse liver. Proc Natl Acad 
Sci U S A. 2007 Jan 30;104(5):1488-93 
Carra S, Seguin SJ, Lambert H, Landry J. HspB8 
chaperone activity toward poly(Q)-containing proteins 
depends on its association with Bag3, a stimulator of 
macroautophagy. J Biol Chem. 2008 Jan 18;283(3):1437-
44 
Dephoure N, Zhou C, Villén J, Beausoleil SA, Bakalarski 
CE, Elledge SJ, Gygi SP. A quantitative atlas of mitotic 
phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 
5;105(31):10762-7 
Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X, 
Madura K, Depre C. Proteasome activation during cardiac 
hypertrophy by the chaperone H11 Kinase/Hsp22. 
Cardiovasc Res. 2008 Feb 1;77(3):497-505 
Shemetov AA, Seit-Nebi AS, Bukach OV, Gusev NB. 
Phosphorylation by cyclic AMP-dependent protein kinase 
inhibits chaperone-like activity of human HSP22 in vitro. 
Biochemistry (Mosc). 2008 Feb;73(2):200-8 
Carra S. The stress-inducible HspB8-Bag3 complex 
induces the eIF2alpha kinase pathway: implications for 
protein quality control and viral factory degradation? 
Autophagy. 2009 Apr;5(3):428-9 
Carra S, Brunsting JF, Lambert H, Landry J, Kampinga 
HH. HspB8 participates in protein quality control by a non-
chaperone-like mechanism that requires eIF2{alpha} 
phosphorylation. J Biol Chem. 2009 Feb 27;284(9):5523-
32 
Fuchs M, Poirier DJ, Seguin SJ, Lambert H, Carra S, 
Charette SJ, Landry J. Identification of the key structural 
motifs involved in HspB8/HspB6-Bag3 interaction. 
Biochem J. 2009 Dec 14;425(1):245-55 
McCollum AK, Casagrande G, Kohn EC. Caught in the 
middle: the role of Bag3 in disease. Biochem J. 2009 Dec 
14;425(1):e1-3 
Sanbe A, Daicho T, Mizutani R, Endo T, Miyauchi N, 
Yamauchi J, Tanonaka K, Glabe C, Tanoue A. Protective 
effect of geranylgeranylacetone via enhancement of 
HSPB8 induction in desmin-related cardiomyopathy. PLoS 
One. 2009;4(4):e5351 
Sui X, Li D, Qiu H, Gaussin V, Depre C. Activation of the 
bone morphogenetic protein receptor by H11kinase/Hsp22 
promotes cardiac cell growth and survival. Circ Res. 2009 
Apr 10;104(7):887-95 
Wilhelmus MM, Boelens WC, Kox M, Maat-Schieman ML, 
Veerhuis R, de Waal RM, Verbeek MM. Small heat shock 
proteins associated with cerebral amyloid angiopathy of 
hereditary cerebral hemorrhage with amyloidosis (Dutch 
type) induce interleukin-6 secretion. Neurobiol Aging. 2009 
Feb;30(2):229-40 
Crippa V, Carra S, Rusmini P, Sau D, Bolzoni E, Bendotti 
C, De Biasi S, Poletti A. A role of small heat shock protein 
B8 (HspB8) in the autophagic removal of misfolded 
proteins responsible for neurodegenerative diseases. 
Autophagy. 2010a Oct;6(7):958-60 
Crippa V, Sau D, Rusmini P, Boncoraglio A, Onesto E, 
Bolzoni E, Galbiati M, Fontana E, Marino M, Carra S, 
Bendotti C, De Biasi S, Poletti A. The small heat shock 
protein B8 (HspB8) promotes autophagic removal of 
misfolded proteins involved in amyotrophic lateral sclerosis 
(ALS). Hum Mol Genet. 2010b Sep 1;19(17):3440-56 
Irobi J, Almeida-Souza L, Asselbergh B, De Winter V, 
Goethals S, Dierick I, Krishnan J, Timmermans JP, 
Robberecht W, De Jonghe P, Van Den Bosch L, Janssens 
S, Timmerman V. Mutant HSPB8 causes motor neuron-
specific neurite degeneration. Hum Mol Genet. 2010 Aug 
15;19(16):3254-65 
Sun X, Fontaine JM, Hoppe AD, Carra S, DeGuzman C, 
Martin JL, Simon S, Vicart P, Welsh MJ, Landry J, 
Benndorf R. Abnormal interaction of motor neuropathy-
associated mutant HspB8 (Hsp22) forms with the RNA 
helicase Ddx20 (gemin3). Cell Stress Chaperones. 2010 
Sep;15(5):567-82 
Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, 
Pearlberg J, Sawyer J, Stevens H, Harlow E, LaBaer J. 
High-throughput ectopic expression screen for tamoxifen 
resistance identifies an atypical kinase that blocks 
autophagy. Proc Natl Acad Sci U S A. 2011 Feb 
1;108(5):2058-63 
Holmes EC. What does virus evolution tell us about virus 
origins? J Virol. 2011 Jun;85(11):5247-51 
Ke L, Meijering RA, Hoogstra-Berends F, Mackovicova K, 
Vos MJ, Van Gelder IC, Henning RH, Kampinga HH, 
Brundel BJ. HSPB1, HSPB6, HSPB7 and HSPB8 protect 
against RhoA GTPase-induced remodeling in tachypaced 
atrial myocytes. PLoS One. 2011;6(6):e20395 
Kirbach BB, Golenhofen N. Differential expression and 
induction of small heat shock proteins in rat brain and 
cultured hippocampal neurons. J Neurosci Res. 2011 
Feb;89(2):162-75 
Modem S, Chinnakannu K, Bai U, Reddy GP, Reddy TR. 
Hsp22 (HspB8/H11) knockdown induces Sam68 
expression and stimulates proliferation of glioblastoma 
cells. J Cell Physiol. 2011 Nov;226(11):2747-51 
Mymrikov EV, Seit-Nebi AS, Gusev NB. Large potentials of 
small heat shock proteins. Physiol Rev. 2011 
Oct;91(4):1123-59 
HSPB8 (heat shock 22kDa protein 8) Bollino D, Aurelian L 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12) 918 
Qiu H, Lizano P, Laure L, Sui X, Rashed E et al.. H11 
kinase/heat shock protein 22 deletion impairs both nuclear 
and mitochondrial functions of STAT3 and accelerates the 
transition into heart failure on cardiac overload. Circulation. 
2011 Jul 26;124(4):406-15 
Rosati A, Graziano V, De Laurenzi V, Pascale M, Turco 
MC. BAG3: a multifaceted protein that regulates major cell 
pathways. Cell Death Dis. 2011 Apr 7;2:e141 
Shemetov AA, Seit-Nebi AS, Gusev NB. Phosphorylation 
of human small heat shock protein HspB8 (Hsp22) by 
ERK1 protein kinase. Mol Cell Biochem. 2011 Sep;355(1-
2):47-55 
Smith CC, Li B, Liu J, Lee KS, Aurelian L. The Levels of 
H11/HspB8 DNA methylation in human melanoma tissues 
and xenografts are a critical molecular marker for 5-Aza-2'-
deoxycytidine therapy. Cancer Invest. 2011 Jul;29(6):383-
95 
Vos MJ, Zijlstra MP, Carra S, Sibon OC, Kampinga HH. 
Small heat shock proteins, protein degradation and protein 
aggregation diseases. Autophagy. 2011 Jan;7(1):101-3 
Aurelian L, Laing JM, Lee KS. H11/HspB8 and Its Herpes 
Simplex Virus Type 2 Homologue ICP10PK Share 
Functions That Regulate Cell Life/Death Decisions and 
Human Disease. Autoimmune Dis. 2012;2012:395329 
Cui XY, Wang N, Yang BX, Gao WF, Lin YM, Yao XR, Ma 
XT. HSPB8 is methylated in hematopoietic malignancies 
and overexpression of HSPB8 exhibits antileukemia effect. 
Exp Hematol. 2012 Jan;40(1):14-21 
Irobi J, Holmgren A, De Winter V et al.. Mutant HSPB8 
causes protein aggregates and a reduced mitochondrial 
membrane potential in dermal fibroblasts from distal 
hereditary motor neuropathy patients. Neuromuscul 
Disord. 2012 Aug;22(8):699-711 
Karthik D, Ilavenil S, Kaleeswaran B, Sunil S, Ravikumar 
S. Proteomic analysis of plasma proteins in diabetic rats by 
2D electrophoresis and MALDI-TOF-MS. Appl Biochem 
Biotechnol. 2012 Mar;166(6):1507-19 
Laure L, Long R, Lizano P, Zini R, Berdeaux A, Depre C, 
Morin D. Cardiac H11 kinase/Hsp22 stimulates oxidative 
phosphorylation and modulates mitochondrial reactive 
oxygen species production: Involvement of a nitric oxide-
dependent mechanism. Free Radic Biol Med. 2012 Jun 1-
15;52(11-12):2168-76 
Nivon M, Abou-Samra M, Richet E, Guyot B, Arrigo AP, 
Kretz-Remy C. NF-κB regulates protein quality control after 
heat stress through modulation of the BAG3-HspB8 
complex. J Cell Sci. 2012 Mar 1;125(Pt 5):1141-51 
Seidel K, Vinet J, Dunnen WF et al.. The HSPB8-BAG3 
chaperone complex is upregulated in astrocytes in the 
human brain affected by protein aggregation diseases. 
Neuropathol Appl Neurobiol. 2012 Feb;38(1):39-53 
Smith CC, Lee KS, Li B, Laing JM, Hersl J, Shvartsbeyn 
M, Aurelian L. Restored expression of the atypical heat 
shock protein H11/HspB8 inhibits the growth of genetically 
diverse melanoma tumors through activation of novel 
TAK1-dependent death pathways. Cell Death Dis. 2012 
Aug 16;3:e371 
Yang Z, Lu Y, Liu J, Wang Y, Zhao X. The chaperone-like 
activity of rat HspB8/Hsp22 and dynamic molecular 
transition related to oligomeric architectures in vitro. 
Protein Pept Lett. 2012 Mar;19(3):353-9 
Arrigo AP. Human small heat shock proteins: protein 
interactomes of homo- and hetero-oligomeric complexes: 
an update. FEBS Lett. 2013 Jun 27;587(13):1959-69 
Crippa V, Boncoraglio A, Galbiati M, Aggarwal T et al.. 
Differential autophagy power in the spinal cord and muscle 
of transgenic ALS mice. Front Cell Neurosci. 2013;7:234 
Marunouchi T, Abe Y, Murata M, Inomata S, Sanbe A, 
Takagi N, Tanonaka K. Changes in small heat shock 
proteins HSPB1, HSPB5 and HSPB8 in mitochondria of 
the failing heart following myocardial infarction in rats. Biol 
Pharm Bull. 2013;36(4):529-39 
Nakhro K, Park JM, Kim YJ, Yoon BR, Yoo JH, Koo H, 
Choi BO, Chung KW. A novel Lys141Thr mutation in small 
heat shock protein 22 (HSPB8) gene in Charcot-Marie-
Tooth disease type 2L. Neuromuscul Disord. 2013 
Aug;23(8):656-63 
Ramírez-Rodríguez G, Babu H, Klempin F et al.. The α 
crystallin domain of small heat shock protein b8 (Hspb8) 
acts as survival and differentiation factor in adult 
hippocampal neurogenesis. J Neurosci. 2013 Mar 
27;33(13):5785-96 
Reddy VS, Raghu G, Reddy SS, Pasupulati AK, 
Suryanarayana P, Reddy GB. Response of small heat 
shock proteins in diabetic rat retina. Invest Ophthalmol Vis 
Sci. 2013 Nov 19;54(12):7674-82 
Rusmini P, Crippa V, Giorgetti E, Boncoraglio A, Cristofani 
R, Carra S, Poletti A. Clearance of the mutant androgen 
receptor in motoneuronal models of spinal and bulbar 
muscular atrophy. Neurobiol Aging. 2013 
Nov;34(11):2585-603 
Sanbe A, Marunouchi T, Abe T, Tezuka Y et al.. 
Phenotype of cardiomyopathy in cardiac-specific heat 
shock protein B8 K141N transgenic mouse. J Biol Chem. 
2013 Mar 29;288(13):8910-21 
Sato T, Hayashi YK, Oya Y, Kondo T, Sugie K et al.. 
DNAJB6 myopathy in an Asian cohort and 
cytoplasmic/nuclear inclusions. Neuromuscul Disord. 2013 
Mar;23(3):269-76 
Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, 
Miki Y, Chow LW, Coombes RC, Sasano H, Shaw JA, 
Giamas G. LMTK3 is implicated in endocrine resistance 
via multiple signaling pathways. Oncogene. 2013 Jul 
11;32(28):3371-80 
Ulbricht A, Eppler FJ, Tapia VE et al.. Cellular 
mechanotransduction relies on tension-induced and 
chaperone-assisted autophagy. Curr Biol. 2013 Mar 
4;23(5):430-5 
Weiss RA, Stoye JP. Virology. Our viral inheritance. 
Science. 2013 May 17;340(6134):820-1 
Bartelt-Kirbach B, Golenhofen N. Reaction of small heat-
shock proteins to different kinds of cellular stress in 
cultured rat hippocampal neurons. Cell Stress 
Chaperones. 2014 Jan;19(1):145-53 
Brambilla R, Morton PD, Ashbaugh JJ et al.. Astrocytes 
play a key role in EAE pathophysiology by orchestrating in 
the CNS the inflammatory response of resident and 
peripheral immune cells and by suppressing remyelination. 
Glia. 2014 Mar;62(3):452-67 
Ospelt C, Camici GG, Engler A, Kolling C, Vogetseder A, 
Gay RE, Michel BA, Gay S. Smoking induces transcription 
of the heat shock protein system in the joints. Ann Rheum 
Dis. 2014 Jul;73(7):1423-6 
This article should be referenced as such: 
Bollino D, Aurelian L. HSPB8 (heat shock 22kDa protein 
8). Atlas Genet Cytogenet Oncol Haematol. 2014; 
18(12):907-918. 
